Read this manager's filing book
Disclosed positions
Bellevue Group AG: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- AMGEN INC
- Ticker
- AMGN
- Class
- COM
- Reported value
- $308,363,286
- Reported amount
- 851,550
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001104659-26-096739Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| AMGEN INC | AMGN | COM | $308,363,286 | 851,550 | SH | None |
| VERTEX PHARMACEUTICALS INC | VRTX | COM | $287,424,867 | 578,634 | SH | None |
| ARGENX SE | ARGX | SPONSORED ADR | $279,258,770 | 301,000 | SH | None |
| GILEAD SCIENCES INC | GILD | COM | $272,739,254 | 2,158,772 | SH | None |
| REVOLUTION MEDICINES INC | RVMD | COM | $196,272,062 | 1,048,014 | SH | None |
| ORUKA THERAPEUTICS INC | ORKA | COM | $157,714,772 | 1,657,190 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $148,566,227 | 1,393,418 | SH | None |
| SCHOLAR ROCK HLDG CORP | SRRK | COM | $134,725,085 | 2,449,547 | SH | None |
| NUVALENT INC | NUVL | COM | $130,078,598 | 1,053,268 | SH | None |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $123,665,169 | 6,731,909 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $115,739,499 | 6,185,970 | SH | None |
| VAXCYTE INC | PCVX | COM | $114,628,582 | 1,971,935 | SH | None |
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $102,143,083 | 188,515 | SH | None |
| INTUITIVE SURGICAL INC | ISRG | COM NEW | $101,332,443 | 254,809 | SH | None |
| REGENERON PHARMACEUTICALS | REGN | COM | $98,077,230 | 157,291 | SH | None |
| CRINETICS PHARMACEUTICALS IN | CRNX | COM | $98,040,400 | 2,620,000 | SH | None |
| BRIDGEBIO PHARMA INC | BBIO | COM | $88,594,406 | 1,189,506 | SH | None |
| IMMUNOCORE HLDGS PLC | IMCR | ADS | $88,526,779 | 2,788,245 | SH | None |
| ABBOTT LABORATORIES | ABT | COM | $85,941,215 | 947,115 | SH | None |
| STRYKER CORPORATION | SYK | COM | $84,522,261 | 268,461 | SH | None |
| MEDTRONIC PLC | MDT | SHS | $77,778,848 | 994,233 | SH | None |
| IONIS PHARMACEUTICALS INC | IONS | COM | $77,090,336 | 972,258 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $75,617,500 | 1,490,000 | SH | None |
| VERA THERAPEUTICS INC | VERA | CL A | $73,410,771 | 1,710,808 | SH | None |
| JADE BIOSCIENCES INC | JBIO | COM NEW | $67,948,671 | 3,057,996 | SH | None |
| EDWARDS LIFESCIENCES CORP | EW | COM | $66,871,108 | 739,234 | SH | None |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $66,204,857 | 1,982,775 | SH | None |
| UNITEDHEALTH GROUP INC | UNH | COM | $61,981,655 | 149,127 | SH | None |
| DEXCOM INC | DXCM | COM | $55,394,634 | 822,489 | SH | None |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $44,652,000 | 1,200,000 | SH | None |
| AVALYN PHARMACEUTICALS INC | AVLN | COM SHS | $44,442,000 | 1,350,000 | SH | None |
| DAMORA THERAPEUTICS INC | DMRA | COM NEW | $42,106,184 | 1,618,846 | SH | None |
| DISC MEDICINE INC | IRON | COM | $40,958,400 | 560,000 | SH | None |
| THERMO FISHER SCIENTIFIC INC | TMO | COM | $40,016,550 | 79,816 | SH | None |
| BOSTON SCIENTIFIC CORP | BSX | COM | $37,884,902 | 887,650 | SH | None |
| ELI LILLY & CO | LLY | COM | $35,841,367 | 29,882 | SH | None |
| CG ONCOLOGY INC | CGON | COM | $35,069,996 | 493,596 | SH | None |
| IDEXX LABS INC | IDXX | COM | $32,523,463 | 61,780 | SH | None |
| RESMED INC | RMD | COM | $28,880,242 | 148,195 | SH | None |
| KRYSTAL BIOTECH INC | KRYS | COM | $28,815,575 | 77,530 | SH | None |
| MONTE ROSA THERAPEUTICS INC | GLUE | COM | $28,798,000 | 1,190,000 | SH | None |
| DANAHER CORP DEL | DHR | COM | $27,399,405 | 143,844 | SH | None |
| JOHNSON & JOHNSON | JNJ | COM | $26,230,022 | 103,280 | SH | None |
| SEAPORT THERAPEUTICS INC | SPTX | COMMON STOCK | $23,892,000 | 1,100,000 | SH | None |
| PALVELLA THERAPEUTICS INC NE | PVLA | COM | $23,687,100 | 155,000 | SH | None |
| ALIGN TECHNOLOGY INC | ALGN | COM | $23,558,429 | 139,680 | SH | None |
| ANNEXON INC | ANNX | COM | $23,411,091 | 4,100,016 | SH | None |
| HUMANA INC | HUM | COM | $23,196,854 | 58,398 | SH | None |
| ELEVANCE HEALTH INC FORMERLY | ELV | COM | $21,830,522 | 56,449 | SH | None |
| TANGO THERAPEUTICS INC | TNGX | COM | $21,700,129 | 694,182 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.